Back to results

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Primary Purpose

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome

Status

Active

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

Palifermin

Lupron

peripheral blood stem cell transplantation

Total-Body Irradiation (TBI)

Thiotepa

Cyclophosphamide

Degarelix

About this trial

This is an interventional treatment trial for Leukemia focused on measuring LUPRON DEPOT, PALIFERMIN, 12-077

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Treatment Portion:

AML in 1st remission - for patients whose AML does not have "good risk" cytogenetic features (i.e. t (8;21), t(15;17), inv 16 without c-kit mutations).
Acute leukemias of ambiguous lineage in ≥ 1st remission
Secondary AML in remission
AML in ≥ 2nd remission
ALL in 1st remission with clinical or molecular features indicating a high risk for relapse; or ALL ≥ 2nd remission
CML failing to respond to or not tolerating imatinib, dasatinib or nilotinib in first chronic phase of disease; CML in accelerated phase, second chronic phase, or in CR after accelerated phase or blast crisis.
Non-Hodgkins lymphoma with chemo responsive disease in any of the following categories:

intermediate or high grade lymphomas who have failed to achieve a first CR or have relapsed following a 1st remission who are not candidates for autologous transplants.

b.ii. any NHL in remission which is considered not curable with chemotherapy alone and not eligible/appropriate for autologous transplant.

Myelodysplastic syndrome (MDS): RA/RCMD with high risk cytogenetic features or transfusion dependence, RAEB-1 and RAEB-2
Chronic myelomonocytic leukemia: CMML-1 and CMML-2.
Patient's age is ≥18 or ≤60 years old
Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status ≥ 70%
Patients must have adequate organ function measured by:

Cardiac: asymptomatic or if symptomatic then LVEF at rest must be > 50% and must improve with exercise.

Pulmonary: asymptomatic or if symptomatic, DLCO > 60% of predicted (corrected for hemoglobin)
Hepatic: < 3xULN ALT and < 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia
Renal: serum creatinine < 1.2 mg/dL or if serum creatinine is outside the normal range, the CrCl > 50 ml/min (measured or calculated/estimated)
Patients have a plan to receive a CD34-selected peripheral blood stem cell transplant with TBI-based conditioning.

Exclusion Criteria:

Active extramedullary disease
Active and uncontrolled infection at time of transplantation
Patients who have undergone a prior allogeneic or autologous stem cell transplant within the previous six months.
Pregnant or breast feeding
HIV infection
Patient is felt to not be a candidate for TBI by the BMT service

Donor Inclusion Criteria:

Donor must be willing and able to undergo PBSC collection.

Sites / Locations

Memorial Sloan Kettering Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

palifermin with Lupron

palifermin with Degarelix

Arm Description

All patients undergo total body irradiation (TBI) on days -9 to -6 & receive thiotepa intravenously (IV) over 2-4 hours on days -5 to -4, cyclophosphamide IV over 30-60 minutes on days -3 to -2, & anti-thymocyte globulin infused over 12 hours on days -3 to -2 Pts undergo T-cell depleted allogeneic hematopoietic stem cell transplant on day 0. Pts will receive a three month depot dose of Lupron 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Pts will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 & no more than 48 hours prior to the start of cytoreduction. Pts will receive three additional daily doses of palifermin the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 & d+2. Pts will receive a further 3-month depot injection of Lupron approximately 3 months (+/- one week) post the first dose.

Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.

Outcomes

Primary Outcome Measures

a CD4+ T cell count of greater than 200

Will be documented by flow cytometry performed in the clinical lab on peripheral blood.

Secondary Outcome Measures

Overall Survival

Overall survival is defined as the time from transplant to death of last follow-up.

Transplant Related Mortality

TRM is defined as death at any time from the commencement of pre-transplant conditioning due to any cause other than disease relapse with the exception of automobile or other accidents.

Incidence of infections

Any bacterial, viral, fungal or parasitic infection that necessitates therapy will be noted.

Relapse

Full Information

NCT ID

NCT01746849

First Posted

December 7, 2012

Last Updated

February 24, 2023

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

Swedish Orphan Biovitrum

1. Study Identification

Unique Protocol Identification Number

NCT01746849

Brief Title

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Official Title

Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Study Type

Interventional

2. Study Status

Record Verification Date

February 2023

Overall Recruitment Status

Active, not recruiting

Study Start Date

December 2012 (undefined)

Primary Completion Date

December 2023 (Anticipated)

Study Completion Date

December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

Swedish Orphan Biovitrum

4. Oversight

5. Study Description

Brief Summary

The purpose of this study is to help determine if palifermin and leuprolide acetate can help the immune system recover faster following a stem cell transplant. Blood stem cells are very young blood cells that grow in the body to become red or white blood cells or platelets. The transplant uses stem cells in the blood from another person. The donor can be a family member or a volunteer donor. This is called an allogeneic stem cell transplant. The investigators want to see if palifermin and leuprolide acetate can help the immune system recover faster after an allogenic transplant because experiments have shown they may be able to do this.

Detailed Description

Patients will be randomized to one of two arms: palifermin with Lupron, and control. The control arm consists of a standard TCD allo-HSCT without the addition of palifermin or Lupron. Patients randomized to receive Lupron will receive a three month depot dose 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Patients assigned to receive palifermin will receive this drug at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction. The preparative regimen to be used for transplants will consist of: hyperfractionated TBI administered in 11 doses over 4 days for a total of 1375 cGy, thiotepa 5 mg/kg/day IV x 2 days and cyclophosphamide with mesna prophylaxis 60 mg/kg/day IV x 2 days. All patients will receive ATG for two doses prior to transplant, except recipients of mismatched grafts (in the GVHD vector) will receive three doses. G-CSF mobilized CD34 PBSCs obtained from the HLA compatible donor will be infused on day 0. Patients assigned to receive palifermin will receive three additional daily doses of the drug, the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 and d+2. Patients assigned to receive Lupron will receive a further 3-month depot injection approximately 3 months (+/- one week) post the first dose. Supportive care will be administered as per the BMT Service guidelines. The conditioning regimen may be modified to allow an extra day during conditioning or prior to the graft infusion if required by donor and/or patient scheduling restrictions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma

Keywords

LUPRON DEPOT, PALIFERMIN, 12-077

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

82 (Actual)

8. Arms, Groups, and Interventions

Arm Title

palifermin with Lupron

Arm Type

Experimental

Arm Description

Arm Title

palifermin with Degarelix

Arm Type

Experimental

Arm Description

Intervention Type

Biological

Intervention Name(s)

Palifermin

Intervention Type

Biological

Intervention Name(s)

Lupron

Intervention Type

Procedure

Intervention Name(s)

peripheral blood stem cell transplantation

Intervention Type

Radiation

Intervention Name(s)

Total-Body Irradiation (TBI)

Intervention Type

Drug

Intervention Name(s)

Thiotepa

Intervention Type

Drug

Intervention Name(s)

Cyclophosphamide

Intervention Type

Drug

Intervention Name(s)

Degarelix

Primary Outcome Measure Information:

Title

a CD4+ T cell count of greater than 200

Description

Will be documented by flow cytometry performed in the clinical lab on peripheral blood.

Time Frame

6 months

Secondary Outcome Measure Information:

Title

Overall Survival

Description

Overall survival is defined as the time from transplant to death of last follow-up.

Time Frame

2 years

Title

Transplant Related Mortality

Description

TRM is defined as death at any time from the commencement of pre-transplant conditioning due to any cause other than disease relapse with the exception of automobile or other accidents.

Time Frame

6 months

Title

Incidence of infections

Description

Any bacterial, viral, fungal or parasitic infection that necessitates therapy will be noted.

Time Frame

2 years

Title

Relapse

Time Frame

12 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

60 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Treatment Portion: AML in 1st remission - for patients whose AML does not have "good risk" cytogenetic features (i.e. t (8;21), t(15;17), inv 16 without c-kit mutations). Acute leukemias of ambiguous lineage in ≥ 1st remission Secondary AML in remission AML in ≥ 2nd remission ALL in 1st remission with clinical or molecular features indicating a high risk for relapse; or ALL ≥ 2nd remission CML failing to respond to or not tolerating imatinib, dasatinib or nilotinib in first chronic phase of disease; CML in accelerated phase, second chronic phase, or in CR after accelerated phase or blast crisis. Non-Hodgkins lymphoma with chemo responsive disease in any of the following categories: intermediate or high grade lymphomas who have failed to achieve a first CR or have relapsed following a 1st remission who are not candidates for autologous transplants. b.ii. any NHL in remission which is considered not curable with chemotherapy alone and not eligible/appropriate for autologous transplant. Myelodysplastic syndrome (MDS): RA/RCMD with high risk cytogenetic features or transfusion dependence, RAEB-1 and RAEB-2 Chronic myelomonocytic leukemia: CMML-1 and CMML-2. Patient's age is ≥18 or ≤60 years old Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status ≥ 70% Patients must have adequate organ function measured by: Cardiac: asymptomatic or if symptomatic then LVEF at rest must be > 50% and must improve with exercise. Pulmonary: asymptomatic or if symptomatic, DLCO > 60% of predicted (corrected for hemoglobin) Hepatic: < 3xULN ALT and < 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia Renal: serum creatinine < 1.2 mg/dL or if serum creatinine is outside the normal range, the CrCl > 50 ml/min (measured or calculated/estimated) Patients have a plan to receive a CD34-selected peripheral blood stem cell transplant with TBI-based conditioning. Exclusion Criteria: Active extramedullary disease Active and uncontrolled infection at time of transplantation Patients who have undergone a prior allogeneic or autologous stem cell transplant within the previous six months. Pregnant or breast feeding HIV infection Patient is felt to not be a candidate for TBI by the BMT service Donor Inclusion Criteria: Donor must be willing and able to undergo PBSC collection.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Miguel Angel Perales, MD

Organizational Affiliation

Memorial Sloan Kettering Cancer Center

Official's Role

Principal Investigator

Facility Information:

Facility Name

Memorial Sloan Kettering Cancer Center

City

New York

State/Province

New York

ZIP/Postal Code

10065

Country

United States

12. IPD Sharing Statement

Links:

URL

http://www.mskcc.org/

Description

Memorial Sloan Kettering Cancer Center

Learn more about this trial

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

We'll reach out to this number within 24 hrs